Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said. CytoRad was initially formed as a separate
Monoclonal antibody developer Cytogen put the finishing touches on its acquisition of sistercompany CytoRad last month. CytoRad will now be a wholly ownedsubsidiary of Cytogen, the Princeton, NJ, company said.
CytoRad was initially formed as a separate company to pay forR&D at Cytogen, but the two firms began feuding last yearand CytoRad cut off funding (SCAN 6/29/94 and 4/20/94). The disputecontributed to a shortfall of millions of dollars in Cytogen'srevenues last year (SCAN 3/1/95).
The acquisition will resolve the differences between the companiesand will assure Cytogen of a stable source of R&D funds. Cytogenbought CytoRad by trading each share of CytoRad stock for 1.5shares of Cytogen common stock, a warrant expiring in 1997 toacquire one share of Cytogen common stock for $8 a share, anda contingent value right (CVR) to receive additional shares ofCytogen stock if certain conditions are met.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.